To assess the health impacts of PEPFAR beyond HIV, particularly in relation to mortality and maternal and child health from 2004 to 2022, highlighting the significance of this time frame.
Key Findings:
PEPFAR was associated with a 23.4% reduction in all-cause mortality rates from 2004 to 2022, despite a temporary uptick during the COVID-19 pandemic.
In PEPFAR's COP countries, the reduction in all-cause mortality was 28.0%, with a similar context of COVID-19's impact.
Maternal mortality was reduced by 29.1% and child mortality by 38.0% relative to the 2004 baseline due to PEPFAR, with noted challenges during the pandemic.
Childhood immunization rates increased significantly in PEPFAR countries, approaching levels seen in comparison countries, despite pandemic disruptions.
Interpretation:
The findings indicate that PEPFAR has had substantial positive spillover effects on overall health outcomes, particularly in mortality and immunization rates, and underscore the potential negative implications of funding changes amidst the COVID-19 pandemic.
Limitations:
Potential unobservable differences between PEPFAR and comparison countries may affect the results, particularly in the context of external health influences.
The analysis does not account for all external factors influencing health outcomes, which could skew the results.
Conclusion:
PEPFAR's investments have led to significant health improvements beyond HIV, emphasizing the critical need for sustained funding and support for broader health initiatives, especially in light of recent policy changes.
